Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide

被引：0
|
作者：
A A N Giagounidis
A Kulasekararaj
U Germing
R Radkowski
S Haase
P Petersen
G Göhring
G Büsche
C Aul
G J Mufti
U Platzbecker
机构：
[1] Katholisches Klinikum Duisburg,
[2] St Johannes Hospital,undefined
[3] King's College Hospital,undefined
[4] Heinrich-Heine-Universität,undefined
[5] Medizinische Hochschule Hannover,undefined
[6] Technische Universität Dresden,undefined
[7] Universitätsklinikum Carl Gustav Carus,undefined
来源：
Leukemia | 2012年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：855 / 858
页数：3
相关论文
共 50 条
  • [21] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [22] Management of del(5q) MDS
    Giagounidis, A.
    LEUKEMIA RESEARCH, 2009, 33 : S27 - S27
  • [23] Long-Term Response in a Patient with del (5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge
    Pisani, Francesco
    Orlandi, Giulia
    Merola, Roberta
    CASE REPORTS IN ONCOLOGY, 2014, 7 (01): : 277 - 284
  • [24] MONITORING OF THERAPEUTIC RESPONSE TO LENALIDOMIDE IN DEL(5Q) MDS USING A RAPID 5-PARAMETER FLOW CYTOMETRIC DEL(5Q)-SCORE
    Oelschlaegel, U.
    Mohr, B.
    Sockel, K.
    Thiede, C.
    Ehninger, G.
    Bornhaeuser, M.
    Platzbecker, U.
    LEUKEMIA RESEARCH, 2015, 39 : S55 - S55
  • [25] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
  • [26] Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
    Giagounidis, AAN
    Germing, U
    Strupp, C
    Hildebrandt, B
    Heinsch, M
    Aul, C
    ANNALS OF HEMATOLOGY, 2005, 84 (09) : 569 - 571
  • [27] Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
    Toribio Castello, Sofia M.
    Lopez-Cadenas, Felix
    Preudhomme, Claude
    Villaverde Ramiro, Angela
    Fenwarth, Laurene
    Lumbreras, Eva
    Gonzalez, Teresa
    Del Rey, Monica
    Xicoy, Blanca
    Renneville, Aline
    Sanchez-Garcia, Joaquin
    Coll, Rosa
    Slama, Bohrane
    Angel Hernandez-Rivas, Jose
    Thepot, Sylvain
    Bernal, Teresa
    Guerci-Bresler, Agnes
    Gotze, Katharina
    Maria Hernandez-Rivas, Jesus
    Fenaux, Pierre
    Del Canizo, Consuelo
    Diez-Campelo, Maria
    BLOOD, 2022, 140 : 9740 - 9743
  • [28] LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICALTRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?
    Toribio Castello, S. M.
    Lopez-Cadenas, F.
    Preudhomme, C.
    Villaverde Ramiro, A.
    Fenwarth, L.
    Lumbreras, E.
    Gonzalez, T.
    Del Rey, M.
    Xicoy, B.
    Renneville, A.
    Sanchez, J.
    Coll, R.
    Slama, B.
    Hernandez Rivas, J. A.
    Thepot, S.
    Bernal, T.
    Guerci-Bresler, A.
    Gotze, K.
    Hernandez Rivas, J. M.
    Fenaux, P.
    Del Canizo, C.
    Campelo, M.
    LEUKEMIA RESEARCH, 2023, 128
  • [29] Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
    Komrokji, R. S.
    List, A. F.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 62 - 68
  • [30] Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
    A. A. N. Giagounidis
    U. Germing
    C. Strupp
    B. Hildebrandt
    M. Heinsch
    C. Aul
    Annals of Hematology, 2005, 84 : 569 - 571
12345